Comparative Pharmacology
Head-to-head clinical analysis: CARDENE versus CARDENE IN 4 8 DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE versus CARDENE IN 4 8 DEXTROSE IN PLASTIC CONTAINER.
CARDENE vs CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.
Calcium channel blocker (dihydropyridine type) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and decreased myocardial contractility.
20-40 mg orally three times daily.
Intravenous: 5 mg/hr initially, titrate by 2.5 mg/hr every 15 minutes based on response; usual maintenance 3-10 mg/hr.
None Documented
None Documented
1.5-2 hours (terminal); prolonged in hepatic impairment (up to 6-8 hours)
2-4 hours (terminal); prolonged in hepatic impairment; clinical context: requires continuous IV infusion for sustained effect
Renal: 60% as metabolites, 10% unchanged; Fecal: 35%
Renal: 55-60% as metabolites, <1% unchanged; biliary/fecal: 35-40%
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker